Evommune says EVO756 misses endpoints in Phase 2b atopic dermatitis trial

• Evommune posted top-line results from a Phase 2b trial of oral EVO756 in adults with moderate-to-severe atopic dermatitis.
• The study missed its primary and secondary endpoints across all doses, prompting Evommune to halt further development of EVO756 in atopic dermatitis.
• EVO756 was generally well tolerated, supporting continued evaluation in migraine prophylaxis.
• Focus shifts to EVO301, an IL-18BP fusion protein, with a Phase 2b trial in atopic dermatitis planned for mid-2027.
• Management cited a balance sheet expected to fund operations into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260908697408) on September 08, 2026, and is solely responsible for the information contained therein.